USFDA nod to Zydus Diabetes drug Empagliflozin
The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.;
Ahmedabad: Drugmaker, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Empagliflozin Tablets USP 10 mg and 25 mg. USRLD: Jardiance.
Empagliflozin is used to lower blood sugar levels in people with type 2 diabetes. It is also used to reduce the risk of stroke, heart attack, or death in people with type 2 diabetes along with heart and blood vessel disease.
Type 2 diabetes (formerly called non-insulin-dependent, or adult-onset) results from the body's ineffective use of insulin. This type of diabetes is largely the result of excess body weight and physical inactivity.
The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.
Read also: Zydus Lifesciences bags USFDA okay for Norepinephrine Bitartrate Injection
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.